BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Colorectal cancer AND NRAS, N-ras, 4893, ENSG00000213281, P01111, NRAS1 AND Treatment
408 results:

  • 1. Epidemiological and clinicopathological features of KRAS, nras, BRAF mutations and MSI in Chinese patients with stage I-III colorectal cancer.
    Wang W; Wang R; Han X; Zhang W; Zhu L; Gu Y
    Medicine (Baltimore); 2024 Apr; 103(14):e37693. PubMed ID: 38579072
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. Concurrent nras-BRAF variants in metastatic colorectal cancer: a Tunisian case report.
    Douik H; Sahraoui G; Jemaà M; Doghri R; Charfi L; Mrad K
    Anticancer Drugs; 2024 Jun; 35(5):462-465. PubMed ID: 38451831
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. Tumor location matters, next generation sequencing mutation profiling of left-sided, rectal, and right-sided colorectal tumors in 552 patients.
    Ciepiela I; Szczepaniak M; Ciepiela P; Hińcza-Nowak K; Kopczyński J; Macek P; Kubicka K; Chrapek M; Tyka M; Góźdź S; Kowalik A
    Sci Rep; 2024 Feb; 14(1):4619. PubMed ID: 38409377
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. Baseline ctDNA gene alterations as a biomarker of survival after panitumumab and chemotherapy in metastatic colorectal cancer.
    Shitara K; Muro K; Watanabe J; Yamazaki K; Ohori H; Shiozawa M; Takashima A; Yokota M; Makiyama A; Akazawa N; Ojima H; Yuasa Y; Miwa K; Yasui H; Oki E; Sato T; Naitoh T; Komatsu Y; Kato T; Mori I; Yamanaka K; Hihara M; Soeda J; Misumi T; Yamamoto K; Yamashita R; Akagi K; Ochiai A; Uetake H; Tsuchihara K; Yoshino T
    Nat Med; 2024 Mar; 30(3):730-739. PubMed ID: 38347302
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. Using tumor habitat-derived radiomic analysis during pretreatment
    Zhao H; Su Y; Wang Y; Lyu Z; Xu P; Gu W; Tian L; Fu P
    Cancer Imaging; 2024 Feb; 24(1):26. PubMed ID: 38342905
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. Site specific genetic differences in colorectal cancer via Next-Generation-Sequencing using a multigene panel.
    Rencuzogullari A; Bisgin A; Erdogan KE; Gumus S; Yalav O; Boga I; Sonmezler O; Eray IC
    Ann Ital Chir; 2023; 94():605-611. PubMed ID: 38131395
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. Sustained Disease Control in Immune Checkpoint Blockade Responders with Microsatellite Instability-high colorectal cancer after treatment Termination.
    Simmons K; Thomas JV; Ludford K; Willis JA; Higbie VS; Raghav KPS; Johnson B; Dasari A; Kee BK; Parseghian CM; Lee MS; Le PH; Morelli MP; Shen JP; Bent A; Vilar E; Wolff RA; Kopetz S; Overman MJ; Morris VK
    Cancer Res Commun; 2023 Dec; 3(12):2510-2517. PubMed ID: 38085001
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. Characteristic Mutational Damages in Gastric and colorectal Adenocarcinomas.
    Yermekova S; Orazgaliyeva M; Goncharova T; Rakhimbekova F; Kaidarova D; Shatkovskaya O
    Asian Pac J Cancer Prev; 2023 Nov; 24(11):3939-3947. PubMed ID: 38019254
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. Prognostic and predictive biomarkers for anti-EGFR monoclonal antibody therapy in RAS wild-type metastatic colorectal cancer: a systematic review and meta-analysis.
    Lu X; Li Y; Li Y; Zhang X; Shi J; Feng H; Yu Z; Gao Y
    BMC Cancer; 2023 Nov; 23(1):1117. PubMed ID: 37974093
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. Overcoming the hurdles: surmounting acquired resistance to anti-EGFR therapy in metastatic colorectal cancer.
    Sackstein PE; Chintapally N; Wilgucki M; Hartley ML; Alqahtani A; Weinberg BA
    Clin Adv Hematol Oncol; 2023 Nov; 21(11):572-583. PubMed ID: 37948593
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. KRAS
    Laurent PA; Milic M; Quevrin C; Meziani L; Liu W; Morel D; Signolle N; Clémenson C; Levy A; Mondini M; Deutsch E
    J Transl Med; 2023 Oct; 21(1):773. PubMed ID: 37907934
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. High In Vitro and In Vivo Activity of BI-847325, a Dual MEK/Aurora Kinase Inhibitor, in Human Solid and Hematologic cancer Models.
    Vuaroqueaux V; Musch A; Peille AL; Kelter G; Weichert L; Metz T; Hendriks HR; Fiebig HH
    Cancer Res Commun; 2023 Oct; 3(10):2170-2181. PubMed ID: 37830744
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. Small molecular inhibitors for KRAS-mutant cancers.
    Wu X; Song W; Cheng C; Liu Z; Li X; Cui Y; Gao Y; Li D
    Front Immunol; 2023; 14():1223433. PubMed ID: 37662925
    [TBL] [Abstract] [Full Text] [Related]  

  • 14. Dynamic Monitoring of Circulating Tumor DNA in Patients With Metastatic colorectal cancer.
    Urbini M; Marisi G; Azzali I; Bartolini G; Chiadini E; Capelli L; Tedaldi G; Angeli D; Canale M; Molinari C; Rebuzzi F; Virga A; Prochowski Iamurri A; Matteucci L; Sullo FG; Debonis SA; Gallio C; Frassineti GL; Martinelli G; Ulivi P; Passardi A
    JCO Precis Oncol; 2023 Sep; 7():e2200694. PubMed ID: 37656949
    [TBL] [Abstract] [Full Text] [Related]  

  • 15. Rapid Reduction of CEA and Stable Metastasis in an
    Kubota Y; Han Q; Morinaga S; Tsunoda T; Hoffman RM
    In Vivo; 2023; 37(5):2134-2138. PubMed ID: 37652473
    [TBL] [Abstract] [Full Text] [Related]  

  • 16. Mutant PIK3CA as a negative predictive biomarker for treatment with a highly selective PIM1 inhibitor in human colon cancer.
    Park YS; Kim J; Ryu YS; Moon JH; Shin YJ; Kim JH; Hong SW; Jung SA; Lee S; Kim SM; Lee DH; Kim DY; Yun H; You JE; Yoon DI; Kim CH; Koh DI; Jin DH
    Cancer Biol Ther; 2023 Dec; 24(1):2246208. PubMed ID: 37621144
    [TBL] [Abstract] [Full Text] [Related]  

  • 17. Lasting response by vertical inhibition with cetuximab and trametinib in KRAS-mutated colorectal cancer patient-derived xenografts.
    Reissig TM; Ladigan-Badura S; Steinberg A; Maghnouj A; Li T; Verdoodt B; Liffers ST; Pohl M; Wolters H; Teschendorf C; Viebahn R; Admard J; Casadei N; Tannapfel A; Schmiegel W; Hahn SA; Vangala DB
    Mol Oncol; 2023 Nov; 17(11):2396-2414. PubMed ID: 37604687
    [TBL] [Abstract] [Full Text] [Related]  

  • 18. Anatomical resection improves relapse-free survival in colorectal liver metastases in patients with KRAS/nras/BRAF mutations or right-sided colon cancer: a retrospective cohort study.
    Chang W; Chen Y; Zhou S; Ren L; Xu Y; Zhu D; Tang W; Ye Q; Wang X; Fan J; Wei Y; Xu J
    Int J Surg; 2023 Oct; 109(10):3070-3077. PubMed ID: 37526097
    [TBL] [Abstract] [Full Text] [Related]  

  • 19. Transcriptional Profiling and Consensus Molecular Subtype Assignment to Understand Response and Resistance to Anti-Epidermal Growth Factor Receptor Therapy in colorectal cancer.
    Chowdhury S; Gupta R; Millstein J; Lin K; Haridas V; Zeineddine MA; Parseghian C; Lenz HJ; Kopetz S; Shen JP
    JCO Precis Oncol; 2023 Jul; 7():e2200422. PubMed ID: 37487150
    [TBL] [Abstract] [Full Text] [Related]  

  • 20. Polyps and colorectal cancer in Serrated Polyposis Syndrome: Contribution of the Classical Adenoma-Carcinoma and Serrated Neoplasia Pathways.
    van Toledo DEFWM; IJspeert JEG; Boersma H; Musler AR; Bleijenberg AGC; Dekker E; van Noesel CJM
    Clin Transl Gastroenterol; 2023 Aug; 14(8):e00611. PubMed ID: 37352472
    [TBL] [Abstract] [Full Text] [Related]  


    [Next]

    of 21.